Timing of Plasmid Cytokine (IL-2/Ig) Administration Affects HIV-1 Vaccine Immunogenicity in HIV-Seronegative Subjects-Reference-Cited by-同舟云学术

Timing of Plasmid Cytokine (IL-2/Ig) Administration Affects HIV-1 Vaccine Immunogenicity in HIV-Seronegative Subjects

Published:2011-09-21 Issue:10 Volume:204 Page:1541-1549
ISSN:1537-6613
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:

Author:

Baden Lindsey R.¹,Blattner William A.²,Morgan Cecilia³,Huang Yunda⁴,Defawe Olivier D.³,Sobieszczyk Magdalena E.⁵,Kochar Nidhi⁴,Tomaras Georgia D.⁶,McElrath M. Juliana³,Russell Nina⁷,Brandariz Kara⁸,Cardinali Massimo⁹,Graham Barney S.¹⁰,Barouch Dan H.⁸,Dolin Raphael⁸,

Affiliation:

1. Department of Medicine, Brigham and Women’s Hospital

2. Department of Medicine, Institute of Human Virology Epidemiology Division, University of Maryland, Baltimore

3. Vaccine and Infectious Disease Division

4. Statistical Center for HIV/AIDS Research & Prevention (SCHARP), Fred Hutchinson Cancer Research Center

5. Division of Infectious Diseases, College of Physicians and Surgeons & Columbia University Medical Center, New York

6. Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina

7. Bill & Melinda Gates Foundation, Global Health Program, Seattle, Washington

8. Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts

9. Division of AIDS

10. Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Link

http://academic.oup.com/jid/article-pdf/204/10/1541/18065397/jir615.pdf

Reference42 articles.

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators;Palella;N Engl J Med,1998

2. Progress in the development of an HIV-1 vaccine;Letvin;Science,1998

3. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine;Graham;J Infect Dis,2006

4. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers;Goepfert;Vaccine,2007

5. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial;Russell;J Acquir Immune Defic Syndr,2007

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Spatiotemporally programming cytokine immunotherapies through protein engineering;Immunological Reviews;2023-07-06

2. Genetic-Based Vaccine Vectors;Plotkin's Vaccines;2023

3. Bio inspired materials for nonviral vaccine delivery;Bioinspired and Biomimetic Materials for Drug Delivery;2021

4. Combination therapies currently under investigation in phase I and phase II clinical trials for HIV-1;Expert Opinion on Investigational Drugs;2020-02-05

5. Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity;Vaccine;2019-05